Literature DB >> 3025754

Pharmacokinetics and pharmacodynamics of captopril in patients undergoing continuous ambulatory peritoneal dialysis.

A Fujimura, H Kajiyama, A Ebihara, K Iwashita, Y Nomura, Y Kawahara.   

Abstract

Pharmacokinetics and pharmacodynamics of captopril were studied in 5 continuous ambulatory peritoneal dialysis (CAPD) patients (including 2 hypertensive patients) after single oral administration of 50 mg captopril. The pharmacokinetic parameters for plasma free unchanged captopril were time to maximal concentration 1.1 +/- 0.3 h, maximal plasma concentration 387 +/- 75 ng X ml-1, elimination half-life 1.0 +/- 0.3 h, and the area under the concentration-time curve 711 +/- 144 ng X h X ml-1. For plasma total captopril (the sum of free unchanged captopril and its disulfide compounds) the values were time to maximal concentration 3.5 +/- 0.6 h and maximal plasma concentration 2,777 +/- 429 ng X ml-1. Captopril was detected in the dialysis fluid in all CAPD patients. Blood pressures in the 2 hypertensive CAPD patients were lower at 24 h after than before captopril administration. These results suggest that captopril may be eliminated by CAPD. In addition, there is a possibility that the antihypertensive effects of captopril may be prolonged in hypertensive CAPD patients.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3025754     DOI: 10.1159/000184014

Source DB:  PubMed          Journal:  Nephron        ISSN: 1660-8151            Impact factor:   2.847


  7 in total

Review 1.  Risk-benefit ratio of angiotensin antagonists versus ACE inhibitors in end-stage renal disease.

Authors:  D A Sica; T W Gehr; A Fernandez
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

Review 2.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

3.  Pharmacokinetics and pharmacodynamics of quinaprilat after low dose quinapril in patients with terminal renal failure.

Authors:  K Wolter; E Fritschka
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 4.  Angiotensin-converting enzyme inhibitors. Relationship between pharmacodynamics and pharmacokinetics.

Authors:  G G Belz; W Kirch; C H Kleinbloesem
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of angiotensin converting enzyme (ACE) inhibitors in renal failure.

Authors:  J Hoyer; K L Schulte; T Lenz
Journal:  Clin Pharmacokinet       Date:  1993-03       Impact factor: 6.447

Review 6.  Pharmacokinetics of captopril in healthy subjects and in patients with cardiovascular diseases.

Authors:  K L Duchin; D N McKinstry; A I Cohen; B H Migdalof
Journal:  Clin Pharmacokinet       Date:  1988-04       Impact factor: 6.447

7.  Fosinopril pharmacokinetics and pharmacodynamics in chronic ambulatory peritoneal dialysis patients.

Authors:  T W Gehr; D A Sica; D M Grasela; I Fakhry; J Davis; K L Duchin
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.